CRS3123 Phase 2 Results Published in The Lancet Infectious Diseases
A landmark Phase 2 randomized controlled trial demonstrates the safety, tolerability, and promising efficacy of CRS3123 as a novel treatment for C. difficile infection.
Read More
Peer-Reviewed Publication
Other News
Crestone Announces Positive Data from Phase 2 Clinical Trial of CRS3123 for C. difficile Infections Published in The Lancet Infectious Diseases
Phase 2 results, multi-omics gut microbiome data, and Phase 3 readiness milestones announced via Business Wire.
Become a Part of Our Projects
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor, a team member, or a participant in our ongoing clinical studies.
Inquiries
Have a question or comment? Follow the link below to contact us about general inquiries.
Careers
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
Investors
If you're interested in becoming an investor to help fund our research and development, contact us today.